Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab for severe COVID-19 in ICU patients
IRCT20200510047383N1Phase 3Completed
- Sponsor
- Arak University of Medical Sciences
- Start
- May 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of tocilizumab in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Arak University of Medical Sciences. Primary endpoints: Clinical symptom improvement, Mortality and 4 more. Started May 2020; status: completed.
02
Drugs
tocilizumab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on IRCT20200510047383N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20200510047383N1.